|
 AC Immune, backed by German billionaire Dietmar Hopp, said it plans
to use proceeds from the IPO to develop products, including
Alzheimer's drug crenezumab.
Crenezumab, which AC Immune licensed to Roche Holding AG's Genentech
division in 2006, targets protein plaques found in brains of
patients with Alzheimer's.
The company told the U.S Securities and Exchange Commission in a
preliminary prospectus that Credit Suisse, Jefferies and Leerink
Partners were underwriting the IPO. (http://1.usa.gov/25xy2wv)
The filing did not reveal how many shares the company planned to
sell or their expected price.
The company intends to list its common stock on the Nasdaq under the
symbol "ACIU."
The amount of money a company says it plans to raise in its first
IPO filings is used to calculate registration fees. The final size
of the IPO could be different.
(Reporting by Richa Naidu)
[© 2016 Thomson Reuters. All rights
reserved.] Copyright 2016 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed. |
|
